Jared S. Nielsen, MD (Chicago, IL), Manjot Gill, MD (Chicago, IL)


To describe an unusual case of idiopathic central retinal vein occlusion (CRVO) in a 12 year old girl, and report successful treatment with intravitreal bevacizumab in this pediatric patient.


Retrospective report of a single case.


A healthy 12 year-old white female presented 3 weeks after painless loss of vision in her right eye (Va: CF2FT). Examination and fluorescein angiogram revealed a nonischemic CRVO with significant macular edema (see Figure 1). Investigational work-up including pediatric examination, hematologic consultation and neuroimaging were entirely normal. Extensive hematologic testing for hypercoaguable states and hyperviscosity syndromes were normal. After considerable discussion with the parents and patient, intravitreal bevacizumab 1.25mg was administered. Following treatment, there was marked improvement in the
fundus appearance with significant decrease in macular edema (see Figure 2). The vision also improved to 20/400 at last follow-up. No adverse effects from intravitreal bevacizumab have been noted thus far.


This case is unique in that is describes one of the youngest cases of CRVO in the literaturethus far as well as describing the use of successful intravitreal bevacizumab in a pediatric patient.
FIGURE 1: Central retinal vein occlusion in the right eye of our 12 year-old patient.
FIGURE 2: Resolution of retinal hemorrhages and edema 6 weeks after intravitreal bevacizumab injection.